z-logo
open-access-imgOpen Access
Photocatalytic degradation of anthracene by biochar-based graphitic carbon nitride
Author(s) -
Syarifah Nurhusna Qadirah Syed Abd Halim,
Noor Aina Mohd Nazri,
N.A.H.M. Nordin
Publication year - 2021
Publication title -
iop conference series. materials science and engineering
Language(s) - English
Resource type - Journals
eISSN - 1757-899X
pISSN - 1757-8981
DOI - 10.1088/1757-899x/1195/1/012053
Subject(s) - biochar , anthracene , melamine , degradation (telecommunications) , chemistry , catalysis , graphitic carbon nitride , photocatalysis , nuclear chemistry , carbon fibers , pollutant , environmental chemistry , materials science , organic chemistry , pyrolysis , composite material , composite number , telecommunications , computer science
Polycyclic aromatic hydrocarbons (PAHs) are persistent and toxic to living organisms, that can be classified as carcinogenic, mutagenic and teratogenic pollutants. In this study, a green photocatalyst of biochar-based graphitic carbon nitride (BC/g-C 3 N4-M) is derived from sugarcane bagasse (SB) and melamine were developed as a potential material for the degradation of PAHs. BC(SB)/g-C3N4-M prepared with varied ratios of melamine to SB and different synthesis temperature were characterized by FTIR, BET and UV-DRS. The efficiency of the catalyst for the degradation of anthracene were investigated further in terms of its efficiency at various pH mediums, catalyst dosage and anthracene initial concentration. Experimental results revealed that g-C 3 N 4 showed better degradation efficiency to anthracene than BC(SB)/g-C 3 N 4 -M. Additionally, the best degradation efficiency of anthracene by g-C 3 N 4 and BC/g-C 3 N 4 -M75% composites were found at pH 3 with 1.0 g/L dosage at 2 ppm and 1 ppm initial concentration, respectively. The catalysts were also discovered to be reusable for 5 cycles with a slight decrease in photocatalytic degradation. The use of agricultural biomass waste in this study could provide a promising approach to water and wastewater treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here